Neuren Pharmaceuticals Limited
NEU.ASXHealth Care
Biopharmaceutical company with a focus on neurological conditions.
Market Data
$14.540
+0.1%$1.8B
62.5x
$0.233
0.00%
-0.1%
Latest Earnings
Appendix 4E and 2025 full year accounts
27 February 2026
Neuren Pharmaceuticals delivered FY2025 NPAT of A$30.4M, down 79% from A$142.0M in 2024, but the decline is entirely attributable to one-time items in the prior year (A$157M from a sales milestone and Priority Review Voucher sale). Underlying recurring revenue — royalties plus finance income — grew 14% to A$76.8M, driven by 15% growth in DAYBUE royalties to A$64.6M as US$391M in net sales were achieved. Looking ahead, Acadia's 2026 sales guidance of US$460-490M implies Neuren royalties of A$70-77M, with pipeline catalyst NNZ-2591 now in Phase 3 for Phelan-McDermid syndrome. Key points: Recurring royalty revenue grew 15% to A$64.6M as DAYBUE net sales reached US$391M in 2025, with unique patient numbers exceeding 1,000 for the first time.; Cash and short-term investments surged to A$296.1M (from A$222.2M), providing a strong balance sheet with no debt and no need for additional funding.; Strong operating cash inflow of A$125.4M in FY2025, reflecting receipt of the FY2024 milestone and Priority Review Voucher proceeds in Q1 2025.
Recent Announcements
Appendix 4E and 2025 full year accounts
Neuren Pharmaceuticals delivered FY2025 NPAT of A$30.4M, down 79% from A$142.0M in 2024, but the decline is entirely attributable to one-time items in the prior year (A$157M from a sales milestone and Priority Review Voucher sale). Underlying recurring revenue — royalties plus finance income — grew 14% to A$76.8M, driven by 15% growth in DAYBUE royalties to A$64.6M as US$391M in net sales were achieved. Looking ahead, Acadia's 2026 sales guidance of US$460-490M implies Neuren royalties of A$70-77M, with pipeline catalyst NNZ-2591 now in Phase 3 for Phelan-McDermid syndrome. Key points: Recurring royalty revenue grew 15% to A$64.6M as DAYBUE net sales reached US$391M in 2025, with unique patient numbers exceeding 1,000 for the first time.; Cash and short-term investments surged to A$296.1M (from A$222.2M), providing a strong balance sheet with no debt and no need for additional funding.; Strong operating cash inflow of A$125.4M in FY2025, reflecting receipt of the FY2024 milestone and Priority Review Voucher proceeds in Q1 2025.
Acadia reports DAYBUE net sales for 2025 and 2026 guidance
Neuren reported strong 2025 performance with DAYBUE royalty income of A$65 million (up 15% YoY) from partner Acadia's US$391 million drug sales. Based on Acadia's 2026 guidance of US$460-490 million DAYBUE sales, Neuren expects royalty income of A$70-77 million in 2026, representing continued strong growth in this rare disease treatment. Key points: DAYBUE royalty income grew 15% to A$65 million in 2025, within guidance range; Q4 2025 royalty income of A$20 million up 21% quarter-on-quarter showing acceleration; Record 1,070 patients received DAYBUE shipments in Q4 2025, continuing strong patient growth
Get real-time alerts for NEU
Receive AI-powered earnings summaries and instant notifications when Neuren Pharmaceuticals Limited releases results.
Register Free